Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984732 | 0.92 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6MAPK14 | |
| SCHEMBL984052 | 0.87 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6MAPK14 | |
| SCHEMBL984625 | 0.82 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6MAPK14 | |
| SCHEMBL985058 | 0.82 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL983263 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6MAPK14 | |
| SCHEMBL980979 | 0.79 | CTNNB1 (0.45) | SLC6A2SLC6A4SLC6A3CYP2D6MAPK14 | |
| SCHEMBL984328 | 0.77 | CYP19A1 (0.52) | CNR1PTGDR2GSK3AGSK3BKMT2A | |
| SCHEMBL984613 | 0.77 | REN (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CNR1 | |
| SCHEMBL986554 | 0.76 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6MAPK14 | |
| SCHEMBL981023 | 0.73 | ATM (0.40) | PTGDR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257545-B1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2257545-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115427-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | SLC6A3, MAOB, TPH2 | SLC6A2 6/4885SLC6A4 8/4885SLC6A3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.